[Industry Prospects] Analysis of China’s AI New Drug Research and Development (AIDD) Industry Development from 2023 to 2028

Core data of this article: types of competitors; corporate layout

AI plays a key role in the research and development of new drugs, accelerating the discovery and design of new drugs by analyzing large amounts of biological and chemical data. It can predict molecular activity, drug interactions and side effects, helping researchers find potential drug candidates. In addition, AI can analyze clinical trial data, optimize trial design, and predict the safety and efficacy of drugs. In addition, AI can also provide each patient with a personalized drug treatment plan based on the patient's genomic and clinical data, improving treatment effectiveness and safety. In general, the application of AI in new drug research and development can accelerate the drug discovery and design process, optimize clinical trials and drug treatment plans, and improve the efficacy and safety of drugs

——Analysis of the industrial chain

The application of artificial intelligence in new drug research and development can be divided into two stages: upstream and midstream. The upstream stage mainly involves the development of software and hardware, including cloud computing platforms, databases, GPU chips, automated laboratories and servers. The midstream stage can be divided into three stages: drug discovery, preclinical research and clinical trials according to the functional layout of the company. The downstream target customers are mainly traditional pharmaceutical companies and CRO companies

At present, my country's upstream companies in the research and development of new AI drugs mainly include Huawei Cloud, Tencent Cloud, Tianshu Zhixin and Intel, while midstream companies include Shenzhen Technology, Yulu Ganhang, Zhiyu Biotech, Tenmai Pharmaceuticals, Molecule Zhixin, Alpha Molecule, ChemicalAI, InsilicoMedicine (Insilico Intelligence), Deepin Zhiyao, Huashen Intelligent Medicine and Zheyuan Technology, etc.

Competitors for AI new drug research and development include start-ups, Internet companies and traditional pharmaceutical companies

Currently, competitors in my country’s AI new drug research and development (AIDD) industry are mainly divided into three categories: Internet giants, traditional pharmaceutical companies and start-ups. Internet companies cooperate with traditional pharmaceutical companies, universities, and start-ups to build software and platforms, and invest in start-ups to enter the industry. Start-ups provide related services to traditional pharmaceutical companies and CRO companies through self-developed software and platforms

——Drug discovery stage: most companies have made relevant arrangements

The drug discovery stage of AI new drug research and development mainly includes target discovery, lead compound research and compound screening, and compound synthesis. At present, most AIDD start-ups in my country have designed, optimized and synthesized lead compounds. They use machine learning (or deep learning) technology to learn massive chemical knowledge and data, establish efficient models, quickly filter "low-quality" compounds, and enrich Collection of potentially effective molecules. In addition, companies represented by Shenzhen Technology, Insilicon Intelligent, and Kehui Intelligent Pharmaceuticals have basically laid out the entire stage of drug discovery.

——The iDrug platform has a wide range of functional layout and is suitable for all types of Internet companies

Currently, my country’s Alibaba, Tencent, ByteDance, Baidu and Huawei and other companies have begun to deploy in the field of AI new drug research and development. Among them, Tencent’s iDrug platform has a wide range of functions, including target discovery, compound screening, lead compound design, optimization, synthesis, ADMET prediction and clinical trial design

For detailed industry research and analysis, please refer to the "China Biopharmaceutical Industry Development Prospects Forecast and Investment Strategic Planning Analysis Report" by the Qianzhan Industry Research Institute

Qianzhan Industry Research Institute provides solutions such as industrial big data, research reports, planning, park planning, investment promotion, maps, smart investment promotion systems, industry status certification, IPO consulting/funding feasibility study, IPO working paper consultation, etc. Any reference to the content of this article in public information disclosure must be authorized by the Qianzhan Industry Research Institute

The above is the detailed content of [Industry Prospects] Analysis of China’s AI New Drug Research and Development (AIDD) Industry Development from 2023 to 2028. For more information, please follow other related articles on the PHP Chinese website!